{
    "ticker": "ADAP",
    "name": "Adaptimmune Therapeutics PLC",
    "description": "Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company focused on the development of T-cell therapies for cancer. Founded in 2008 and headquartered in Oxford, UK, Adaptimmune specializes in the harnessing of the body\u2019s own immune system to recognize and attack cancer cells. The company\u2019s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform is designed to specifically target and destroy cancer cells that express unique antigens. Adaptimmune has been at the forefront of developing innovative treatments for various types of cancer, including solid tumors and hematologic malignancies. The company's lead product candidates include ADP-A2M4, aimed at treating patients with soft tissue sarcoma, and ADP-A2M4CD8, targeting head and neck cancer. Adaptimmune is committed to advancing its pipeline and has numerous ongoing clinical trials to evaluate the safety and efficacy of its therapies. The company\u2019s mission is to provide transformative therapies that improve the lives of cancer patients while addressing the significant unmet medical needs in oncology. With a dedicated team of scientists, clinicians, and industry veterans, Adaptimmune is poised to make a significant impact in the field of cancer immunotherapy.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Oxford, United Kingdom",
    "founded": "2008",
    "website": "https://www.adaptimmune.com",
    "ceo": "James Noble",
    "social_media": {
        "twitter": "https://twitter.com/adaptimmune",
        "linkedin": "https://www.linkedin.com/company/adaptimmune/"
    },
    "investor_relations": "https://ir.adaptimmune.com",
    "key_executives": [
        {
            "name": "James Noble",
            "position": "CEO"
        },
        {
            "name": "Rebecca O'Connor",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cancer Therapies",
            "products": [
                "ADP-A2M4",
                "ADP-A2M4CD8"
            ]
        }
    ],
    "seo": {
        "meta_title": "Adaptimmune Therapeutics PLC | Cancer Immunotherapy",
        "meta_description": "Adaptimmune Therapeutics PLC is a leader in T-cell therapies for cancer, focusing on developing innovative treatments to improve patient outcomes. Explore our pipeline and mission.",
        "keywords": [
            "Adaptimmune",
            "Cancer Immunotherapy",
            "T-cell Therapy",
            "SPEAR T-cells",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Adaptimmune known for?",
            "answer": "Adaptimmune is known for its innovative T-cell therapies for cancer, utilizing its proprietary SPEAR platform."
        },
        {
            "question": "Who is the CEO of Adaptimmune?",
            "answer": "James Noble is the CEO of Adaptimmune Therapeutics PLC."
        },
        {
            "question": "Where is Adaptimmune headquartered?",
            "answer": "Adaptimmune is headquartered in Oxford, United Kingdom."
        },
        {
            "question": "What are Adaptimmune's main product candidates?",
            "answer": "Adaptimmune's main product candidates include ADP-A2M4 and ADP-A2M4CD8."
        },
        {
            "question": "When was Adaptimmune founded?",
            "answer": "Adaptimmune was founded in 2008."
        }
    ],
    "competitors": [
        "KITE",
        "CRSP",
        "BMY",
        "JNJ"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "ILMN"
    ]
}